Novel Medicines for Immune-Mediated Diseases
Spero Therapeutics (sperotherapeutics.com) scores 75 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 44th percentile of 17127 Healthcare brands.
Spero Therapeutics is a clinical-stage biopharmaceutical company headquartered in Cambridge, United States, focused on developing novel medicines for immune-mediated diseases. Its lead program, SP001, is a third-generation anti-CD40L antibody being developed for IgG4-related disease. The company targets upstream immune cascade mechanisms to reduce disease activity without broadly eliminating immune cells, aiming to address rare and underserved immune conditions with therapies differentiated from existing treatments.
| Brand Name | Spero Therapeutics |
|---|---|
| Domain | sperotherapeutics.com |
| Industry | Healthcare |
| Headquarters | Cambridge |
| Main Competitors | Zenas BioPharma (71/100), Sanofi (90/100), argenx (83/100), UCB (89/100), Immunovant (76/100), Amgen (90/100) |
Moz Domain Authority 39/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Spero Therapeutics develops novel medicines for immune-mediated diseases, beginning with SP001, an anti-CD40L antibody for IgG4-related disease." (Meta description: 17 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram; no detected presence on Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Spero Therapeutics?", Claude could identify the brand as of October 2026. Spero Therapeutics is a biopharmaceutical company focused on developing therapies for multi-drug-resistant bacterial infections and rare diseases. Its lead product, tebipenem pivoxil hydrobromide, is an oral carbapenem antibiotic developed to treat complicated urinary tract infec Best known for Developing tebipenem pivoxil, an oral carbapenem antibiotic for drug-resistant infections.
When asked "Best brands similar to Spero Therapeutics?", Claude would recommend Spero Therapeutics as of October 2026. It's a notable name in the antibiotic resistance space, particularly for its oral carbapenem candidate, so it would come up in discussions of companies tackling multi-drug-resistant infections.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Spero Therapeutics's main competitors in Healthcare: Zenas BioPharma (71/100), Sanofi (90/100), argenx (83/100), UCB (89/100), Immunovant (76/100).
Sources: Brand Analyzer scan
Spero Therapeutics has limited AI-search visibility, scoring 32/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 36, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Spero Therapeutics official site
Spero Therapeutics is headquartered in Cambridge. Spero Therapeutics operates in the Healthcare category.
Sources: Wikidata
Spero Therapeutics' primary offering is SP001, a third-generation anti-CD40L antibody being developed as a treatment for IgG4-related disease, an immune-mediated condition.
Sources: Spero Therapeutics official site
Spero Therapeutics develops targeted immunotherapies for immune-mediated diseases, beginning with SP001, a third-generation anti-CD40L antibody for IgG4-related disease, designed to act upstream in the immune cascade to reduce disease activity without broadly eliminating immune cells.
Sources: Spero Therapeutics official site
Spero Therapeutics scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Spero Therapeutics official site
Spero Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, United States, that develops medicines for immune-mediated diseases.
Sources: Spero Therapeutics official site
Spero Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Spero Therapeutics official site
Spero Therapeutics is known for developing SP001, an anti-CD40L antibody targeting IgG4-related disease, a rare immune-mediated condition.
Sources: Spero Therapeutics official site
Spero Therapeutics' work is relevant to patients with rare, immune-mediated diseases such as IgG4-related disease, as well as physicians, researchers, and investors in the biopharmaceutical and rheumatology fields.
Sources: Spero Therapeutics official site
Spero Therapeutics scores 32/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Spero Therapeutics has a weak AI-visibility profile at 32/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 39/100 and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Spero Therapeutics from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Spero Therapeutics: Speech Therapy PD (75/100), Specsavers (75/100), SPI Pharma (75/100), Standard Imaging (75/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.